Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

NCT03449654 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication liraglutide on reducing vascular inflammation in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind prevention study

Participants 102 people

Who can join Ages 50+ · all sexes

Timeline Started 2017-10 · est. completion 2019-08

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT03449654 ↗

Description as written by the study sponsor.

The objective of this study is to evaluate the mechanism behind the anti-atherogenic effects of liraglutide. In a randomized, placebo-controlled, double-blind, parallel trial we will included 100 patients with type 2 diabetes. Patients will be randomized 1:1 to an active treatment period of 26 weeks or placebo for 26 weeks. The primary endpoint is change from baseline to week 26 in vascular inflammation, assessed by Flour Deoxy Glucose (FDG)-Positron Emission Tomography/Computed Tomography (PET/CT)

Treatments tested

Liraglutide Drug

Liraglutid
Placebo (for liraglutide) Drug

Placebo (for liraglutide)

Main thing measured	Change in vascular inflammation
Sponsor	Steno Diabetes Center Copenhagen
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03449654 ↗